Search This Blog

Thursday, June 25, 2026

Bio-Techne to be acquired by Merck for $73 per share in cash, value $11.3B

 

Bio-Techne to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, valuing deal at $11.3B

  • Acquisition is subject to approval by Bio-Techne shareholders and required regulatory clearances.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)